Taiho Pharmaceutical Co., Ltd. (Taiho)

Oncology Corporate Profile

HQ Location

1-27 Kandanishiki-cho
Chiyoda-ku, Tokyo

Company Description

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing evidence-based medicines for the treatment of cancer.

Website: http://www.taiho.co.jp/english/

Brand Generic Indication
LONSURF«• trifluridine (+ tipiracil)LONSURF«• is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated withfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TAS-102antitumor agentColorectal cancerIII
TAS-102antitumor agentGastric CancerIII
TAS-118antimetaboliteGastric CancerIII
TAS-118antimetabolitePancreatic CancerIII
TAS-116HSP90 inhibitor_Gastrointestinal Stromal Tumors (GIST)II
TAS-114dUTPase inhibitorNon Small Cell Lung Cancer (NSCLC)II
trabectedine / ET-743guanine N7 inhibitorOvarian cancerI
TAS3681AR agonistProstate cancerI
TAS-115ATP inhibitorVarious cancer typesI
TAS-119aurora a inhibitorVarious cancer typesI
TAS-117AKT inhibitorVarious cancer typesI
TAS-121EGFR selective inhibitorVarious cancer typesI
TAS-120FGFR inhibitorVarious cancer typesI

View additional information on product candidates here »

Source


http://www.taiho.co.jp/english/

Recent News Headlines

There are no news items to display